A biotech stock’s value is not the same thing as the chance that one of its drugs will be approved. Approval odds estimate whether a particular candidate will clear development and regulatory hurdles; stock valuation asks what the company’s entire portfolio and other assets may be worth after costs, time, financing needs, debt and commercial uncertainty. Investors should compare both—but keep those questions separate until they translate each drug’s risks and potential cash flows into an estimate of the company’s equity value.
What drug approval odds tell you—and what they do not
An approval probability is an estimate about a specific drug candidate, indication and regulatory path. It is not a probability that the company will succeed, and it does not tell you whether the stock is cheap. A company can have a promising candidate but an expensive share price; another may have a less certain lead asset but meaningful cash, partnerships or other pipeline programs. Even a candidate that wins approval may not generate enough sales to justify its development costs or the company’s market value.
As an Amazon Associate I earn from qualifying purchases.
Keep three probabilities distinct:
- Probability of approval: The chance that a candidate, based on its current evidence and remaining development, receives marketing authorization for a defined use. The regulatory details here concern U.S. Food and Drug Administration (FDA) review.
- Probability of commercial success: The chance that an approved product reaches meaningful adoption and earns a return after competition, pricing and reimbursement, manufacturing, launch costs and remaining exclusivity.
- Probability of a positive stock return: The chance that shareholders earn a gain from the price they pay. This also depends on what the market already expects, the company’s financing and the valuation investors assign to future cash flows.
These are connected, but none can be substituted for another. The value of a drug asset depends on its probability-weighted economics; the value of the stock depends on all material assets and obligations, plus the number of shares over which the equity is divided.
Why a phase label is not an approval probability
Phase tells you broadly where a candidate is in development, not its chance of success. That chance depends on the indication, drug modality, trial design, endpoint, size and consistency of the effect, safety profile, regulatory route and remaining evidence burden. A Phase 3 candidate with weak or inconclusive results is not equivalent to another Phase 3 candidate with persuasive evidence.
#1 Best Overall
The FDA’s consumer overview describes a typical sequence from preclinical work through Phase 1, Phase 2 and Phase 3 to a new drug application (NDA) submission. Its broad sample-size descriptions are 20–80 participants for Phase 1, a few dozen to about 300 for Phase 2, and several hundred to about 3,000 for Phase 3. These are general descriptions, not requirements or reliable measures of an individual program’s odds. The FDA reviews evidence submitted by the sponsor; it does not conduct the sponsor’s clinical trials.
Phase-transition rates can be useful inputs, but pooled rates are only priors. A 2020 article by Miller, Rabinovitz and Kerr questioned how well rates aggregated across therapeutic areas represent individual diseases. Before applying any quoted success rate to a candidate, check the dataset’s date, diseases and modalities, phases covered, denominator and definition of “success.” The evidence available here does not establish a current, indication-specific probability table that can responsibly be applied to an unnamed asset. In particular, there is no support for a blanket claim such as “Phase 3 means X% odds of approval.”
FDA review statistics answer a different question. The FDA reported in 2025 that 37 of the 50 novel drugs it approved through its Center for Drug Evaluation and Research (CDER) in 2024 were approved on the first review cycle, and 33 of those 50 used one or more expedited programs. Those figures describe drugs that were already approved; they are not the odds that an unapproved candidate will reach approval.
What’s actually slowing this PC down?
Pick the symptom - the matching free tool is one click away.
How to turn drug risk into a valuation
A common framework is risk-adjusted net present value, or rNPV. It estimates the present value of a candidate’s potential future cash flows while adjusting for development success, phase-specific costs and time. The World Intellectual Property Organization’s 2025 guide describes rNPV as a widely used method for biotech assets and firms and recommends scenario analysis instead of relying on one outcome.
In practical terms, estimate the cash flows the drug could generate in each year, multiply them by the probability that the candidate reaches the relevant development or commercial outcome, account for costs when they would be incurred, then discount the resulting cash flows to reflect time and the cost of capital. A simplified representation is:
Asset rNPV = present value of probability-weighted future net cash flows − present value of probability-weighted remaining development costs.
Make the assumptions explicit. Development-success probability and the discount rate are conceptually separate: use the probability adjustment for development risk and the discount rate for time and capital cost. Hiding development risk in a very high discount rate—or applying the same risk twice—can obscure what drives the result. A 2019 peer-reviewed open-access model paper describes rNPV inputs such as drug type, stage, phase attrition and development period, while noting that attrition and development-time evidence can be limited or inconsistent in some areas. A model disciplines assumptions; it does not make uncertain inputs precise.
Value after approval is still uncertain. FDA approval permits marketing under the approved labeling; it does not guarantee sales or profitability. Forecast the addressable patient population, likely uptake, competition, pricing and reimbursement, manufacturing and commercialization costs, and remaining exclusivity. Build downside, base and upside cases rather than treating a single sales forecast as certain. Analysis Group’s 2024 practitioner guide illustrates probability-weighted phase-specific research and development costs and post-commercialization value, while emphasizing that assumptions can vary substantially across drugs.
Compare the stock on more than clinical stage
Use the following axes to assess what may be priced into a biotech company. The candidate’s evidence informs probability and timing; the company’s economics and capital structure determine how much of the resulting value reaches shareholders.
Rank #4
| What to compare | Questions to ask | Why it matters |
|---|---|---|
| Clinical evidence | What is the trial phase and design? Is there a control group? What are the primary endpoint, effect size, confidence interval, durability, safety findings and consistency across relevant subgroups? | Evidence quality affects the remaining uncertainty, development time and likely cost to a regulatory decision. |
| Probability of success | What are the stage-conditional and overall probabilities, and do they fit this indication, modality, endpoint and program-specific evidence? | A pooled industry rate may not describe an individual disease or candidate. |
| Regulatory path | Is the expected application an NDA or biologics license application (BLA)? Are the endpoint and evidence package acceptable? What FDA feedback is public, and are confirmatory trials required? | Regulatory requirements shape the evidence burden, timing and costs still ahead. |
| Asset economics | How many patients may be eligible? Who are the competitors? What uptake, net revenue, manufacturing, launch and exclusivity assumptions are plausible? | Approval opens the opportunity to market under a label; forecast sales remain uncertain. |
| Time and cost | When are trials, readouts and launch expected? What spending is required at each stage, and how much runway remains? | Delay reduces present value and may require more capital before a value-changing milestone. |
| Financing and equity | What are cash, debt, burn rate, diluted shares, options or convertibles, partnership economics and likely financing needs? | Company obligations and future share issuance affect the value attributable to each share. |
| Portfolio and market price | What other developed assets, earlier pipeline programs, platform options or partnerships are supported by evidence? What assumptions are implied by market capitalization or enterprise value? | A lead candidate may not represent a multi-asset company, and a plausible drug does not by itself establish that its stock is undervalued. |
How to assess FDA designations and endpoints
The FDA has four broadly applicable expedited programs for drugs intended to treat serious conditions: fast track, breakthrough therapy, priority review and accelerated approval. They can facilitate development or review in specified circumstances; a designation is not a guarantee of approval. Read what the designation changes for the particular program rather than treating it as proof that the drug works.
Accelerated approval may allow certain products to rely on a surrogate endpoint that is reasonably likely to predict clinical benefit, with confirmatory evidence obligations. The FDA says whether a surrogate endpoint is acceptable for an individual drug or biologic development program is determined case by case; the agency’s table of surrogate endpoints is updated every six months. For a candidate using this pathway, include the confirmatory-trial requirement and its timing, cost and potential consequences in the valuation assumptions.
Free tools Windows power users keep installed
One-click scans. No signup required.
The FDA’s 2023 benefit-risk guidance describes assessment of a drug’s benefits, risks and risk-management options. In practice, examine the actual trial protocol and results, endpoint, effect size and safety findings, as well as public regulatory feedback and any confirmatory obligations. A designation or a favorable headline about one endpoint does not replace that evidence.
A practical workflow for comparing a candidate with its stock
- Inventory the company’s material assets. Record each program, indication and current stage. Separate lead candidates from earlier platform possibilities, and note partnerships or other assets only where their economics are supportable.
- Build a probability tree for each candidate. Estimate the chance of reaching the next phase and the chance of eventual approval conditional on current evidence. Separately estimate commercial success after approval. State the population and assumptions behind each probability; do not multiply unrelated generic rates as though they describe this asset.
- Forecast cases, dates and spending. For downside, base and upside scenarios, set out milestones, development costs by phase, likely launch timing, revenue, operating costs and remaining exclusivity. Probability-weight relevant inflows and phase-specific costs, then discount for time and capital cost.
- Aggregate asset values and bridge to equity. Sum supported asset values and separately justified platform or partnership value. Add cash and other assets, subtract debt and other claims, then account for dilution from options, convertibles or expected financing. Dividing an indicative equity value by diluted shares gives a per-share framework, not a precise target price.
- Stress-test the assumptions. Vary probability of success, enrollment or readout delays, endpoint effect, penetration, net revenue, competitor entry, development costs, discount rate and financing dilution. Identify which changes alter the conclusion most.
- Compare with the quoted valuation. Look at market capitalization and enterprise value alongside the scenario range. Ask what success, timing and commercial assumptions the current price appears to require; do not assume the market has overlooked an asset simply because its approval chance seems plausible.
What can and cannot be concluded without a named company
Without the company, candidate, indication, trial results, share count, financial statements and financing plan, no company-specific fair value or approval probability can be calculated. The framework can show what an investor should compare, but a numerical conclusion requires asset-level clinical evidence and company-level financial inputs. Treat any model output as a range whose assumptions can be challenged—not as a fact about what the stock should trade at.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
